PF-04634817

Unknown / undisclosed

DiscontinuedCCR2/CCR5 chemokine receptorsNo recent registered activity
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued, after a negative readout

PF-04634817 was Pfizer's oral CCR2/CCR5 chemokine receptor antagonist, taken to phase 2 in diabetic nephropathy and diabetic macular edema. This Pfizer-authored report of the diabetic nephropathy phase 2 states that clinical development was discontinued because the albuminuria reduction was too modest; the drug had also failed non-inferiority against ranibizumab in diabetic macular edema. The paper gives no date for the decision. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Phase 1 (4)
Other / comorbidity
NCT01791855 · Pfizer
2013-05-10 – 2013-09-03 · Renal Insufficiency
What this study did
NCT01247883 · Pfizer
2010-10 – 2010-12 · Healthy
What this study did
NCT01140672 · Pfizer
2010-06 – 2010-10 · Healthy
What this study did
NCT01098877 · Pfizer
2010-04 – 2010-09 · Healthy
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.